Sandostatin Stungulyf, lausn 100 míkróg/ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin stungulyf, lausn 100 míkróg/ml

novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 100 míkróg/ml

Sandostatin Stungulyf, lausn 50 míkróg/ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin stungulyf, lausn 50 míkróg/ml

novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 50 míkróg/ml

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 10 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 10 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 10 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 20 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 20 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 20 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 30 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 30 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 30 mg

Mycapssa الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

mycapssa

amryt pharmaceuticals dac - octreotide acetate - acromegaly - hinsveiflur og heilahimnubólur og hliðstæður - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Certican Tafla 0,75 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

certican tafla 0,75 mg

novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg

Certican Tafla 0,5 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

certican tafla 0,5 mg

novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg

Certican Tafla 0,25 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

certican tafla 0,25 mg

novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg

Insulin aspart Sanofi الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

insulin aspart sanofi

sanofi winthrop industrie - insúlín aspart - sykursýki - lyf notuð við sykursýki - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.